2019
Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.
Verplaetse TL, Roberts W, Moore KE, Peltier MR, Oberleitner LM, McKee SA. Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers. Journal Of Clinical Psychopharmacology 2019, 39: 124-128. PMID: 30707118, PMCID: PMC6391212, DOI: 10.1097/jcp.0000000000001004.Peer-Reviewed Original ResearchConceptsAdult daily smokersDoses of guanfacineAdverse eventsMedication levelsDaily smokersTobacco cravingTreatment-emergent adverse eventsExtended-release formulationSimilar pharmacokinetic profileAttention deficit hyperactivity disorderDry mouthLast doseMigraine prophylaxisBlood pressureHeroin withdrawalStable dosingDose equivalencyHeart rateER formulationSmoking outcomesGuanfacinePharmacokinetic profileDrug AdministrationVital signsHyperactivity disorder
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesA preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers
Roberts W, Verplaetse TL, Moore KE, Oberleitner LM, McKee SA. A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers. Human Psychopharmacology Clinical And Experimental 2018, 33: e2660. PMID: 29878501, PMCID: PMC5995328, DOI: 10.1002/hup.2660.Peer-Reviewed Original ResearchConceptsContinuous performance taskInhibitory controlCognitive functioningPerformance taskTobacco withdrawalEffects of doxazosinSustained attentionCognitive performanceWithdrawal symptomsCognitive AssessmentSmoking outcomesMost measuresSelf-reported withdrawal symptomsReaction timeTaskParticipantsFunctioningPredrug levelsΑ1 antagonistTitration periodGreater improvementDoxazosinSmokingSymptomsPreliminary investigationEffects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkersPilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior
Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, Tetrault JM, Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. Journal Of Psychopharmacology 2018, 32: 1003-1009. PMID: 29692206, PMCID: PMC6258014, DOI: 10.1177/0269881118767647.Peer-Reviewed Original ResearchConceptsEffects of carvedilolSmoking lapse behaviorAdrenergic antagonistsTobacco cravingSmoking outcomesPhysiologic reactivitySystolic blood pressureNumber of cigarettesNicotine-motivated behaviors× time effectSelf-administration periodEffects of α1Human laboratory modelNicotine-deprived smokersPlacebo groupBlood pressureAdrenergic antagonismMedication conditionClinical indicationsNoradrenergic systemSubsequent smokingHeart rateProperties of drugsSmokingCarvedilol
2015
The Relationship Between Childhood Physical and Emotional Abuse and Smoking Cessation Among U.S. Women and Men
Smith PH, Saddleson ML, Homish GG, McKee SA, Kozlowski LT, Giovino GA. The Relationship Between Childhood Physical and Emotional Abuse and Smoking Cessation Among U.S. Women and Men. Psychology Of Addictive Behaviors 2015, 29: 338-346. PMID: 25347015, PMCID: PMC4486346, DOI: 10.1037/adb0000033.Peer-Reviewed Original ResearchConceptsSerious psychological distressChildhood maltreatmentQuit attemptsActual quit attemptsCurrent cigarette smokersSuccessful quit attemptsU.S. adult smokersNational U.S. sampleLikelihood of smokingFemale smokersPsychological distressSmoking cessationCigarette smokersAdult smokersSmoking outcomesSmokingMore difficultyMaltreatmentSmokersU.S. sampleLower likelihoodTelephone surveyPath modelingMotivationWomenTargeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomenSystematic and Meta-Analytic Review of Research Examining the Impact of Menstrual Cycle Phase and Ovarian Hormones on Smoking and Cessation
Weinberger AH, Smith PH, Allen SS, Cosgrove KP, Saladin ME, Gray KM, Mazure CM, Wetherington CL, McKee SA. Systematic and Meta-Analytic Review of Research Examining the Impact of Menstrual Cycle Phase and Ovarian Hormones on Smoking and Cessation. Nicotine & Tobacco Research 2015, 17: 407-421. PMID: 25762750, PMCID: PMC4429881, DOI: 10.1093/ntr/ntu249.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseHormone levelsOvarian hormonesLuteal phaseSmoking behaviorSearch termsOvarian hormone levelsMenstrual phase effectsCessation-related behaviorsTiming of interventionNegative subjective effectsMenstrual cycle effectsProgesterone administrationFollicular phaseMedication responseQuit ratesTonic cravingInclusion criteriaMenstrual phaseNonsignificant trendSmoking outcomesCycle phaseSmokingSystematic reviewGreater tonic
2014
A behavioural smoking treatment based on perceived risks of quitting: A preliminary feasibility and acceptability study with female smokers
Weinberger AH, Pittman B, Mazure CM, McKee SA. A behavioural smoking treatment based on perceived risks of quitting: A preliminary feasibility and acceptability study with female smokers. Addiction Research & Theory 2014, 23: 108-114. PMID: 25904837, PMCID: PMC4402999, DOI: 10.3109/16066359.2014.933813.Peer-Reviewed Original ResearchFemale smokersPoint prevalence smoking abstinenceStage II clinical trialsEnd of treatmentDaily cigarette smokersTreatment development studyNovel behavioral treatmentPrimary outcomeCigarette smokersSmoking abstinenceSmoking interventionsClinical trialsMayo ClinicStandard counselingRisk counselingSmoking treatmentSmoking outcomesSmokersBehavioral treatmentManualized treatmentTreatment developmentAcceptability studyCounseling conditionMonthsGreater reduction
2007
Confirmatory Factor Analysis of the Minnesota Nicotine Withdrawal Scale
Toll BA, O’Malley S, McKee SA, Salovey P, Krishnan-Sarin S. Confirmatory Factor Analysis of the Minnesota Nicotine Withdrawal Scale. Psychology Of Addictive Behaviors 2007, 21: 216-225. PMID: 17563141, PMCID: PMC2527730, DOI: 10.1037/0893-164x.21.2.216.Peer-Reviewed Original ResearchConceptsMinnesota Nicotine Withdrawal ScaleWithdrawal ScaleTotal scorePoorer smoking outcomesClinical studiesClinical research samplesSmoking outcomesChange scoresStudy sampleConfirmatory factor analysisGood internal consistency estimatesScoresFactor analysisFuture investigatorsSmokersSyndromeSymptomsFactor scores